摘要
目的观察高通量血液透析(HFHD)联合左卡尼汀改善维持性血液透析(MHD)患者贫血的疗效及安全性。方法将伴有贫血的MHD患者60例,按使用透析器不同和是否应用左卡尼汀随机分为4组,分别为A组(低通量血液透析)、B组(低通量血液透析+左卡尼汀)、C组(高通量血液透析)、D组(高通量血液透析+左卡尼汀),每组各15例。观察4组患者贫血治疗的效果及不良反应发生情况。结果治疗后,A组患者贫血指标没有明显改善;B、C、D组患者贫血指标有所改善,与A组比较,差异有统计学意义(P<0.05)。D组患者贫血指标较B、C组疗效显著,组间比较,差异有统计学意义(P<0.05)。D组患者发生不良反应少于A、B、C组,组间比较,差异有统计学意义(P<0.05)。结论高通量血液透析联合左卡尼汀治疗MHD患者贫血疗效显著,安全性高,值得推广。
Objective To explore the efficacy and safety of high-flux hemodialysis（ HFDH） combined with L-carnitine treatment of maintenance hemodialysis（ MHD） patients with anemia. Methods A retrospective study was performed on 60 cases of MHD patients with anemia. According to different dialysis methods and whether use L-carnitine or not,60 cases were randomly divided into 4 groups with 15 cases in each group. There were Group A（ low-flux hemodialysis group） ,Group B（ low-flux hemodialysis＋L-carnitine group） , Group C（ high-flux hemodialysis group） and Group D（ high-flux hemodialysis＋L-carnitine group） . Clinical features such as treatment effect and the incidence of adverse reaction in 4 groups were observed and analized. Results After treatment,the anemia indicators in Group A were not improved,while those in Group B,C and D were improved statistically compared with those in Group A（P〈0. 05）. The curative effect in Group D was statistically better compared with group B and C（P〈0. 05）. The incidence of adverse reaction in Group D was statistically less than that in Group A,B and C（P〈0. 05）. Conclusion HFDH combined with L-carnitine for treating MHD patients with anemia has obvious curative effect and high safety,it′s worth being clinical promoted.
出处
《临床军医杂志》
CAS
2016年第4期402-404,407,共4页
Clinical Journal of Medical Officers
基金
卫生公益性行业科研专项合作项目(201002010)
